Aligos Therapeutics Inc (ALGS): ALGS discontinues another HBV candidate:...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	827
Posts	119469
Boards Moderated	15
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 3

Tuesday, 03/22/2022 9:43:35 AM

Tuesday, March 22, 2022 9:43:35 AM

ALGS discontinues another HBV candidate:

https://finance.yahoo.com/news/aligos-discontinues-development-antisense-oligonucleotide-120000830.html

Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”